New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation

Coates, LC; Murphy, Ruth; Helliwell, Philip S.

doi:10.1111/bjd.14667

Cited by 38 publications

(27 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Originally, TNF-a inhibitors were recommended as the first-line biologic agents against PsA; 25 however, more recently other classes of biologic agents have also been recommended. 26 As expected, in our study TNF-a inhibitors (IFX/ADA) were the most frequently employed biologic agent for first-line treatment (76.2% of patients), 52.6% of participants receiving them as a secondline treatment. TNF inhibitors were continued in 105 individuals and discontinued in 47.…”

Section: Treatmentsupporting

confidence: 82%

Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitors

Tsuruta

Narisawa

Imafuku

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is an inflammatory arthritis with as yet unclear pathophysiology. This retrospective, multicenter, cross‐sectional study was conducted in 19 facilities in western Japan and aimed to identify patients’ characteristics and factors that affect the results of treatment with biologic agents. Of 2116 patients with psoriasis, 285 (13.5%) had PsA. Skin manifestations preceded joint manifestations in 69.8%, the onset was simultaneous in 17.2%, whereas PsA preceded skin manifestations in 2.5%. Peripheral arthritis was most common, occurring in 73.7%, compared with axial disease in 21.8%, enthesitis in 23.5% and dactylitis in 35.4%. Patients with severe skin manifestations were significantly younger at onset (P = 0.02) and more frequently had axial disease (P < 0.01). Biologic agents were used in 206 patients (72.3%), anti‐tumor necrosis factor (TNF)‐α antibodies being prescribed first to 157 of them. Anti‐TNF‐α antibodies were continued by 105 participants and discontinued by 47, the remaining five patients being lost to follow up. Patients who discontinued anti‐TNF‐α antibodies were significantly older than those who continued (55 vs 51 years, P = 0.04) and significantly older at onset of joint manifestations (50 vs 44 years, P = 0.01). Multivariate analysis revealed that patients over 50 years significantly more frequently terminated anti‐TNF‐α antibodies (P < 0.01). In conclusion, patients with PsA and severe skin manifestations have earlier onset and axial disease, which seriously impacts on quality of life. Anti‐TNF‐α antibodies were generally effective enough to continue but less so in patients aged over 50 years. Further detailed research is needed.

show abstract

Section: Treatmentsupporting

confidence: 82%

Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitors

Tsuruta

Narisawa

Imafuku

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…International treatment recommendations have been published and are based on available evidence and expert opinion [2]. Such recommendations outline the different treatments that are considered efficacious for the six main domains of PsD.…”

Section: Overview Of the Marketmentioning

confidence: 99%

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Berekméri

Mahmood

Wittmann

et al. 2018

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Psoriasis and psoriatic arthritis (PsA) are inflammatory immune-mediated conditions which can cause considerable disability and reduced quality of life. Management can be complex as clinical heterogeneity may lead to different treatment pathways. Tofacitinib is a novel, oral Janus Kinase (JAK) inhibitor with proven efficacy in rheumatoid arthritis. Areas covered: This review analyzes recent studies of tofacitinib in psoriatic disease treatment. The relevant literature was identified using clinicaltrials.gov, PubMed, and Google Scholar. Tofacitinib efficacy was demonstrated in PsA by the OPAL Broaden and OPAL Beyond phase-III studies, and received FDA and EMA approval. Tofacitinib was superior to placebo for the treatment of moderate-to-severe plaque psoriasis in the OPT Pivotal 1 and 2, OPT Retreatment studies, but FDA approval was declined for this indication based on issues of clinical efficacy and long-term safety. Expert commentary: Tofacitinib is an important oral drug for the treatment of PsA. However, the long-term safety data require further evaluation. Tofacitinib and other JAK inhibitors show potential to broaden the treatment options in PsA and other inflammatory conditions.

show abstract

“…Stiffness, independence, treatment burden, and sleep were added to the research agenda for evaluation as possible domains [35–37]. Further research will be aimed at developing patient-centered therapeutic pathways that target both skin and joint manifestations [38]. …”

Section: Recent Omeract Publicationsmentioning

confidence: 99%

Incorporating the patient's perspective in outcomes research

Hsiao

Fraenkel

2017

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Incorporation of the patients’ perspective in clinical research is critical to ensure that outcomes measured reflect those, which matter most to patients. This review summarizes recent efforts to include the patients’ perspective in the development of outcome measures and the importance of encouraging patient participation in decision-making and self-management. Recent findings Since the inclusion of fatigue as a patient-endorsed core outcome measure in rheumatoid arthritis (RA) trials, OMERACT has been instrumental in advocating for patient involvement in the development of core domains and instruments; current endeavors include cultivating an understanding of remission through the eyes of patients and gaining a sense of how to measure features of pain and ‘stiffness’ deemed as important to patients. The concept of remission was further explored in RA patients, highlighting a common goal of returning to normality; additionally, various tools have been developed to assess for unmet needs in rheumatology patients. Advances have also been made in the development and revision of patient-centered core measures in rheumatologic diagnoses outside of RA. Summary Incorporating the patients’ perspective is now considered an essential feature in outcomes research. Future research should focus on how best to involve patients in specific research activities.

show abstract

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation

Cited by 38 publications

References 6 publications

Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitors

Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitors

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Incorporating the patient's perspective in outcomes research

Contact Info

Product

Resources

About